A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
Author:
Affiliation:
1. Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden
2. Pfizer Inc; La Jolla California USA
Publisher
Wiley
Subject
Pharmacology (medical),Modeling and Simulation
Reference51 articles.
1. EAU guidelines on renal cell carcinoma: 2014 update;Ljungberg;Eur. Urol.,2015
2. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms;Rothermundt;World J. Urol.,2016
3. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 2012
4. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial;Rini;Lancet Oncol.,2013
5. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial;Hutson;Clin. Genitourin. Cancer,2017
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach;The AAPS Journal;2024-08-08
2. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model;International Immunopharmacology;2024-01
3. Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer;CPT: Pharmacometrics & Systems Pharmacology;2023-10-25
4. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment;PLOS Computational Biology;2023-10-04
5. Efficacy and Safety of First-Line Cytokines Versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study;Cancers;2023-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3